MicroViable Therapeutics is a science-based biotech, born in 2016 as a startup from the Spanish National Research Council (CSIC) and located in the beautiful area of Gijón (Asturias, Spain).

Our goal is to develop next generation biotherapeutics based on complex communities from the intestinal microbiota. The microbiota-based therapeutics can be implemented as adjuvants in certain disease where a microbiota dysbiosis (alteration) exist. Examples of this dysbiosis occurred in antibiotic-associated diarrhea, inflammatory bowel disease (IBD), cancer treatments and Clostridium difficile infection.

Our team

Microviable Therapeutics has assembled an experienced team of leaders in intestinal microbiota, probiotics and human health, and biotech business development to drive our technology into tangible products and clinic development.

Rafael martínez Permuy
MBA
Chief Executive Officer and Co-Founder
Business development and product management
DRA. NOELIA MARTÍNEZ
PhD
Chief Scientific Officer and Co-Founder
R&D director leading the microbiota team
DR. ABELARDO MARGOLLES
PhD
Scientific Advisory Board and Co-Founder
Senior Scientist and Group Leader at IPLA-CSIC
DRA. SUSANA DELGADO
PhD
Scientific Advisory Board and Co-Founder
Senior Scientist at IPLA-CSIC
DR. BORJA SÁNCHEZ
PhD
Scientific Advisory Board and Co-Founder
Senior Scientist at IPLA-CSIC
DR. CLAUDIO HIDALGO
PhD
Scientific Advisory Board and Co-Founder
Scientist at North Carolina State University
Investors

We are thankful and grateful to PadeInvest and the private investors for their support.

Partners
Certifications
Awards